Session » Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 996

Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard

9:00AM-11:00AM: Abstract Number: 999

Association between Smoking with Spinal Level of Stiffness and Functional Limitation in Patients with Axial Spondyloarthritis: Results from the Spanish Atlas

9:00AM-11:00AM: Abstract Number: 977

Association of Leisure-Time Physical Activity with Late-Life Mobility Limitation Among Women with Total Joint Replacement for Hip or Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 988

Association of Ultraviolet-B Radiation and Risk of SLE Among Women in the Nurses’ Health Studies

9:00AM-11:00AM: Abstract Number: 987

Death Certificates Do Not Accurately Identify SLE Patients

9:00AM-11:00AM: Abstract Number: 978

Dietary Patterns and Risk of Developing Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 986

Do Death Certificates Underestimate the Burden of Rare Diseases: The Example of Systemic Lupus Erythematosus Mortality in Sweden

9:00AM-11:00AM: Abstract Number: 982

Epidemiology and Mortality in Systemic Sclerosis in South Korea: A Nationwide Population-Based Study

9:00AM-11:00AM: Abstract Number: 985

Heart Failure Hospitalizations Among SLE and Diabetes Mellitus Patients Compared to the General U.S. Medicaid Population

9:00AM-11:00AM: Abstract Number: 990

Higher Omega-6 to Omega-3 Fatty Acid Ratio Is Associated with Increased Odds of Inflammatory Arthritis in a Health Fair Population Positive for Anti-Citrullinated Protein Antibodies (ACPA)

9:00AM-11:00AM: Abstract Number: 984

Identification of Key Screening Characteristics for Systemic Lupus Erythematosus Natural History

9:00AM-11:00AM: Abstract Number: 983

Identifying Exposures to Chemicals in Patients with SLE – a Non-Targeted Exposome Approach Reveals Enrichment for Phthalates

9:00AM-11:00AM: Abstract Number: 989

Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis

9:00AM-11:00AM: Abstract Number: 997

Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors

9:00AM-11:00AM: Abstract Number: 993

Increase in Prevalence of Psoriasis Arthritis over Time: Analysis of Claims Data from 65 Million People in Germany from 2009 to 2012

9:00AM-11:00AM: Abstract Number: 994

Increasing Population Burden of Psoriatic Disease in Ontario, Canada – a Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 980

Is Intra-Articular Injection of Synvisc Associated with a Delay to Knee Arthroplasty in Knee OA Patients?

9:00AM-11:00AM: Abstract Number: 998

Mental Health in Patients with Axial Spondyloarthritis: Increasing Our Understanding of the Disease. Results from the Spanish Atlas

9:00AM-11:00AM: Abstract Number: 1001

Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy

9:00AM-11:00AM: Abstract Number: 991

Publication Timeliness of the Randomized Controlled Trials of Drug Therapy for Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1002

Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)

9:00AM-11:00AM: Abstract Number: 981

The Common Risk Factors for Hyperuricemia and Gout Do Not Predict Incident Gout Once Hyperuricemia Is Established

9:00AM-11:00AM: Abstract Number: 992

The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra

9:00AM-11:00AM: Abstract Number: 995

The Epidemiology of Psoriatic Arthritis in Israel – a Population-Based Study

9:00AM-11:00AM: Abstract Number: 1000

Use of Mutual Information Theory in Development and Refinement of a Predictive Model for Early Identification of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 979

What Have We Learned from Trajectory Analysis of Clinical Outcomes in Osteoarthritis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].